Roche generated slightly higher sales in the first nine months of 2025 than a year ago. Sales rose to 45.9 billion Swiss ...

Shares in Roche fell 1% during the third quarter, but rose 8.4% since the beginning of the year through Tuesday's close. WHAT TO WATCH:--DRUG PRICING: The impact of President Trum ...

Swiss drugmaker Roche on Thursday lifted its full-year guidance after reporting nine-month sales that were better than ...

For years, MASH was where drug development dreams went to die.  | After Rezdiffra’s approval and Wegovy’s label expansion, ...

A pair of antibody-based biotech deals emerged late this week, encompassing separate licensing pacts from China’s Hansoh Pharma and California-based Rani Therapeutics, which together represent bill | ...

The drug is the only medicine of its kind proven to help patients with lupus nephritis regain full kidney response, the ...

Chinese biotech Hansoh Pharma said on Friday it had signed a licence agreement worth up to $1.45 billion with Roche for an ...

Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

The US Food and Drug Administration (FDA) has granted approval for Roche's Gazyva/ Gazyvaro (obinutuzumab) to treat adult ...

Shares of China’s Hansoh Pharmaceutical edged up 2% to HK$36.50 as it announced a license agreement with Roche for HS-20110, ...

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. After two generics makers ...

Eli Lilly (LLY -0.82%) is the most valuable healthcare stock in the world, with a market capitalization of more than $760 ...